{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:16:58Z","timestamp":1790702218203,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":175,"publisher":"Springer US","isbn-type":[{"value":"9781071612040","type":"print"},{"value":"9781071612057","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-1-0716-1205-7_41","type":"book-chapter","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T07:03:16Z","timestamp":1615446196000},"page":"591-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment"],"prefix":"10.1007","author":[{"given":"Mohammad A.","family":"Obeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A. A.","family":"Aljabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Rezigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Amawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanin","family":"Alyamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha N.","family":"Abdeljaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"20","key":"41_CR1","doi-asserted-by":"publisher","first-page":"30011","DOI":"10.1016\/j.addr.2020.02.005","volume":"S0169-409X","author":"LN Borgheti-Cardoso","year":"2020","unstructured":"Borgheti-Cardoso LN, Viegas JSR, Silvestrini AVP, Caron AL, Pra\u00e7a FG, Kravicz M, Bentley MVLB (2020) Nanotechnology approaches in the current therapy of skin cancer. Adv Drug Deliv Rev S0169-409X(20):30011\u201330019. https:\/\/doi.org\/10.1016\/j.addr.2020.02.005","journal-title":"Adv Drug Deliv Rev"},{"key":"41_CR2","unstructured":"American Cancer Society (2019) Skin cancer, cancer facts and figures 2019"},{"issue":"1","key":"41_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16(1):5\u201324","journal-title":"Oncologist"},{"issue":"1","key":"41_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller AJ, Mihm MC (2006) Melanoma. New Engl J Med 355(1):51\u201365. https:\/\/doi.org\/10.1056\/NEJMra052166","journal-title":"New Engl J Med"},{"key":"41_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/B978-0-12-397927-8.00012-9","volume":"65","author":"SV Madhunapantula","year":"2012","unstructured":"Madhunapantula SV, Robertson GP (2012) Chemoprevention of melanoma. Adv Pharmacol 65:361\u2013398. https:\/\/doi.org\/10.1016\/B978-0-12-397927-8.00012-9","journal-title":"Adv Pharmacol"},{"issue":"1","key":"41_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10565-018-9446-9","volume":"35","author":"AM Szasz","year":"2019","unstructured":"Szasz AM, Malm J, Rezeli M, Sugihara Y, Betancourt LH, Rivas D, Gyorffy B, Marko-Varga G (2019) Challenging the heterogeneity of disease presentation in malignant melanoma\u2014impact on patient treatment. Cell Biol Toxicol 35(1):1\u201314","journal-title":"Cell Biol Toxicol"},{"key":"41_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-4614-6176-0_10","volume":"779","author":"MS Evans","year":"2013","unstructured":"Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ (2013) Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol 779:223\u2013255. https:\/\/doi.org\/10.1007\/978-1-4614-6176-0_10","journal-title":"Adv Exp Med Biol"},{"issue":"13","key":"41_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/jco.2013.52.7564","volume":"32","author":"H Eriksson","year":"2014","unstructured":"Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, Naredi P, Stierner U, Carstensen J, Hansson J (2014) Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. J Clin Oncol 32(13):1356\u20131364. https:\/\/doi.org\/10.1200\/jco.2013.52.7564","journal-title":"J Clin Oncol"},{"issue":"5","key":"41_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jnci\/91.5.446","volume":"91","author":"J Aitken","year":"1999","unstructured":"Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91(5):446\u2013452. https:\/\/doi.org\/10.1093\/jnci\/91.5.446","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"41_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1046\/j.0022-202x.2001.01421.x","volume":"117","author":"C Kennedy","year":"2001","unstructured":"Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN (2001) Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117(2):294\u2013300. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01421.x","journal-title":"J Invest Dermatol"},{"issue":"9","key":"41_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1365-4632.2010.04474.x","volume":"49","author":"DL Narayanan","year":"2010","unstructured":"Narayanan DL, Saladi RN, Fox JL (2010) Ultraviolet radiation and skin cancer. Int J Dermatol 49(9):978\u2013986","journal-title":"Int J Dermatol"},{"issue":"8","key":"41_CR12","first-page":"410","volume":"110","author":"J Lapins","year":"2013","unstructured":"Lapins J, Emtestam L, Hedblad MA, Girnita A, Lindelof B, Ljung A, Hansson J (2013) Synchronous multiple primary melanoma are often missed. Increased attention to the patient\u2019s entire skin is required for early diagnosis. Lakartidningen 110(8):410\u2013412","journal-title":"Lakartidningen"},{"key":"41_CR13","unstructured":"Cancer Stat Facts: Melanoma of the Skin. National cancer institute, Surrveillance Epidemiology and End Results (SEER) program (2019)"},{"key":"41_CR14","volume-title":"Pharmacotherapy principles and practice","author":"MA Chisholm-Burns","year":"2019","unstructured":"Chisholm-Burns MA, Wells BG, Schwinghammer TL (2019) Pharmacotherapy principles and practice, 5th edn. McGraw-Hill, New York","edition":"5"},{"issue":"1","key":"41_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.soc.2010.09.005","volume":"20","author":"NG Rao","year":"2011","unstructured":"Rao NG, Yu HH, Trotti A 3rd, Sondak VK (2011) The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am 20(1):115\u2013131. https:\/\/doi.org\/10.1016\/j.soc.2010.09.005","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"41_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jso.21962","volume":"104","author":"MI Ross","year":"2011","unstructured":"Ross MI, Gershenwald JE (2011) Evidence-based treatment of early-stage melanoma. J Surg Oncol 104(4):341\u2013353","journal-title":"J Surg Oncol"},{"issue":"1","key":"41_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/jco.2003.07.173","volume":"21","author":"MF Demierre","year":"2003","unstructured":"Demierre MF, Nathanson L (2003) Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 21(1):158\u2013165. https:\/\/doi.org\/10.1200\/jco.2003.07.173","journal-title":"J Clin Oncol"},{"issue":"19","key":"41_CR18","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1101\/gad.12.19.3008","volume":"12","author":"AW Lin","year":"1998","unstructured":"Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK\/MAPK mitogenic signaling. Genes Dev 12(19):3008\u20133019. https:\/\/doi.org\/10.1101\/gad.12.19.3008","journal-title":"Genes Dev"},{"issue":"6","key":"41_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.0022-202x.2001.01601.x","volume":"117","author":"M Stas","year":"2001","unstructured":"Stas M, Degreef H, Demunter A, De Wolf-Peeters C, van den Oord JJ (2001) Analysis of N- and K-Ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 117(6):1483\u20131489. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01601.x","journal-title":"J Invest Dermatol"},{"key":"41_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2018.00202","volume":"8","author":"H Helgadottir","year":"2018","unstructured":"Helgadottir H, Rocha Trocoli Drakensj\u00f6 I, Girnita A (2018) Personalized medicine in malignant melanoma: towards patient tailored treatment. Front Oncol 8:202\u2013202. https:\/\/doi.org\/10.3389\/fonc.2018.00202","journal-title":"Front Oncol"},{"issue":"1","key":"41_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1040-8428(02)00014-8","volume":"44","author":"R Molife","year":"2002","unstructured":"Molife R, Hancock B (2002) Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hemat 44(1):81\u2013102","journal-title":"Crit Rev Oncol Hemat"},{"issue":"1","key":"41_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1741-7015-10-23","volume":"10","author":"L Finn","year":"2012","unstructured":"Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Med 10(1):23. https:\/\/doi.org\/10.1186\/1741-7015-10-23","journal-title":"BMC Med"},{"key":"41_CR23","volume-title":"Cutaneous melanoma: etiology and therapy","author":"MP Rausch","year":"2017","unstructured":"Rausch MP, Hastings KT (2017) Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application. In: Cutaneous melanoma: etiology and therapy. Codon Publications, Singapore"},{"key":"41_CR24","volume-title":"Melanoma, cancer treatment and research","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Flaherty CR, Postow MA (2016) Checkpoint blockade for the treatment of advanced melanoma. In: Kaufman H, Mehnert J (eds) Melanoma, cancer treatment and research. Springer, Cham"},{"key":"41_CR25","unstructured":"NCCN Giudlines. National comprehensive Cancer Network (2019) https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed 10 Oct 2019"},{"key":"41_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fonc.2018.00526","volume":"8","author":"F Del Bufalo","year":"2018","unstructured":"Del Bufalo F, Ceglie G, Cacchione A, Alessi I, Colafati GS, Carai A, Diomedi-Camassei F, De Billy E, Agolini E, Mastronuzzi A, Locatelli F (2018) BRAF V600E inhibitor (vemurafenib) for BRAF V600E mutated low grade gliomas. Front Oncol 8:526\u2013526. https:\/\/doi.org\/10.3389\/fonc.2018.00526","journal-title":"Front Oncol"},{"issue":"20","key":"41_CR27","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867\u20131876. https:\/\/doi.org\/10.1056\/NEJMoa1408868","journal-title":"N Engl J Med"},{"issue":"7","key":"41_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandala M, Haanen J, Lebbe C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381(7):626\u2013636. https:\/\/doi.org\/10.1056\/NEJMoa1904059","journal-title":"N Engl J Med"},{"key":"41_CR29","volume-title":"Drug transporters in drug disposition, effects and toxicity","author":"H Amawi","year":"2019","unstructured":"Amawi H, Sim H-M, Tiwari AK, Ambudkar SV, Shukla S (2019) ABC transporter-mediated multidrug-resistant cancer. In: Liu X, Pan G (eds) Drug transporters in drug disposition, effects and toxicity. Springer, Singapore"},{"issue":"14","key":"41_CR30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2217\/nnm-2017-0145","volume":"12","author":"I Badea","year":"2017","unstructured":"Badea I (2017) New strategies in melanoma therapy: can nanoparticles overcome chemoresistance? Nanomedicine 12(14):1623\u20131626. https:\/\/doi.org\/10.2217\/nnm-2017-0145","journal-title":"Nanomedicine"},{"issue":"3","key":"41_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/ijo.2014.2502","volume":"45","author":"E Agostinelli","year":"2014","unstructured":"Agostinelli E, Condello M, Tempera G, Macone A, Bozzuto G, Ohkubo S, Calcabrini A, Arancia G, Molinari A (2014) The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: a new therapeutic approach. Int J Oncol 45(3):1109\u20131122","journal-title":"Int J Oncol"},{"issue":"5","key":"41_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/00313020412331282690","volume":"36","author":"P Heenan","year":"2004","unstructured":"Heenan P (2004) Local recurrence of melanoma. Pathology 36(5):491\u2013495","journal-title":"Pathology"},{"issue":"4","key":"41_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.20079","volume":"86","author":"U Leiter","year":"2004","unstructured":"Leiter U, Meier F, Schittek B, Garbe C (2004) The natural course of cutaneous melanoma. J Surg Oncol 86(4):172\u2013178. https:\/\/doi.org\/10.1002\/jso.20079","journal-title":"J Surg Oncol"},{"issue":"3","key":"41_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/08982104.2018.1531424","volume":"29","author":"MA Obeid","year":"2018","unstructured":"Obeid MA, Duf\u00e8s C, Somani S, Mullen AB, Tate RJ, Ferro VA (2018) Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown. J Liposome Res 29(3):229\u2013238. https:\/\/doi.org\/10.1080\/08982104.2018.1531424","journal-title":"J Liposome Res"},{"issue":"3","key":"41_CR35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bcp.12987","volume":"82","author":"K Sridharan","year":"2016","unstructured":"Sridharan K, Gogtay NJ (2016) Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol 82(3):659\u2013672. https:\/\/doi.org\/10.1111\/bcp.12987","journal-title":"Br J Clin Pharmacol"},{"key":"41_CR36","volume-title":"From nucleic acids sequences to molecular medicine","author":"S Pushpendra","year":"2012","unstructured":"Pushpendra S, Arvind P, Anil B (2012) Nucleic acids as therapeutics. In: Erdmann VA, Barciszewski J (eds) From nucleic acids sequences to molecular medicine. Springer, Berlin"},{"key":"41_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1567201817666200106104332","volume":"17","author":"S Garima","year":"2020","unstructured":"Garima S, Hamid AB, Alaa AA, Vijay M, Lukmanul Hakkim F, Nitin BC, Prashant K, Dinesh Kumar C, Kamal D, Murtaza MT (2020) Nucleic acid aptamers as a potential nucleus targeted drug delivery system. Curr Drug Deliv 17:1\u201311. https:\/\/doi.org\/10.2174\/1567201817666200106104332","journal-title":"Curr Drug Deliv"},{"issue":"12","key":"41_CR38","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1073\/pnas.87.12.4499","volume":"87","author":"D Yu","year":"1990","unstructured":"Yu D, Suen TC, Yan DH, Chang LS, Hung MC (1990) Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 87(12):4499\u20134503. https:\/\/doi.org\/10.1073\/pnas.87.12.4499","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"41_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4155\/tde-2018-0051","volume":"10","author":"H Alyamani","year":"2019","unstructured":"Alyamani H, Obeid MA, Tate RJ, Ferro VA (2019) Exosomes: fighting cancer with cancer. Ther Deliv 10(1):37\u201361. https:\/\/doi.org\/10.4155\/tde-2018-0051","journal-title":"Ther Deliv"},{"issue":"2 Pt 2","key":"41_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0092-8674(80)90358-x","volume":"22","author":"MR Capecchi","year":"1980","unstructured":"Capecchi MR (1980) High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 22(2 Pt 2):479\u2013488. https:\/\/doi.org\/10.1016\/0092-8674(80)90358-x","journal-title":"Cell"},{"issue":"4","key":"41_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034833","volume":"7","author":"C Lu","year":"2012","unstructured":"Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA (2012) Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 7(4):e34833. https:\/\/doi.org\/10.1371\/journal.pone.0034833","journal-title":"PLoS One"},{"issue":"3","key":"41_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/gt.2009.159","volume":"17","author":"K Anwer","year":"2010","unstructured":"Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17(3):360\u2013369. https:\/\/doi.org\/10.1038\/gt.2009.159","journal-title":"Gene Ther"},{"issue":"6","key":"41_CR43","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.juro.2013.12.011","volume":"191","author":"ON Gofrit","year":"2014","unstructured":"Gofrit ON, Benjamin S, Halachmi S, Leibovitch I, Dotan Z, Lamm DL, Ehrlich N, Yutkin V, Ben-Am M, Hochberg A (2014) DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol 191(6):1697\u20131702. https:\/\/doi.org\/10.1016\/j.juro.2013.12.011","journal-title":"J Urol"},{"issue":"13","key":"41_CR44","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108(13):4009\u20134017. https:\/\/doi.org\/10.1182\/blood-2006-04-015024","journal-title":"Blood"},{"issue":"1","key":"41_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","volume":"9","author":"JC Kaczmarek","year":"2017","unstructured":"Kaczmarek JC, Kowalski PS, Anderson DG (2017) Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Mede 9(1):60. https:\/\/doi.org\/10.1186\/s13073-017-0450-0","journal-title":"Genome Mede"},{"key":"41_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-94-007-5590-1_1","volume":"774","author":"TA Farazi","year":"2013","unstructured":"Farazi TA, Hoell JI, Morozov P, Tuschl T (2013) MicroRNAs in human cancer. Adv Exp Med Biol 774:1\u201320. https:\/\/doi.org\/10.1007\/978-94-007-5590-1_1","journal-title":"Adv Exp Med Biol"},{"issue":"6956","key":"41_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature01957","volume":"425","author":"Y Lee","year":"2003","unstructured":"Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956):415\u2013419. https:\/\/doi.org\/10.1038\/nature01957","journal-title":"Nature"},{"issue":"8","key":"41_CR48","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15(8):509\u2013524. https:\/\/doi.org\/10.1038\/nrm3838","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"41_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2010.09.008","volume":"143","author":"KS Kosik","year":"2010","unstructured":"Kosik KS (2010) MicroRNAs and cellular phenotypy. Cell 143(1):21\u201326. https:\/\/doi.org\/10.1016\/j.cell.2010.09.008","journal-title":"Cell"},{"issue":"20","key":"41_CR50","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.4161\/cc.26087","volume":"12","author":"J Chou","year":"2013","unstructured":"Chou J, Shahi P, Werb Z (2013) microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 12(20):3262\u20133271. https:\/\/doi.org\/10.4161\/cc.26087","journal-title":"Cell Cycle"},{"key":"41_CR51","volume-title":"Lipid nanocarriers for drug targeting","author":"MA Obeid","year":"2018","unstructured":"Obeid MA, Tate RJ, Mullen AB, Ferro VA (2018) Lipid-based nanoparticles for cancer treatment. In: Grumezescu AM (ed) Lipid nanocarriers for drug targeting. Elsevier, Amsterdam"},{"issue":"4","key":"41_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nbt1081","volume":"23","author":"AD Judge","year":"2005","unstructured":"Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23(4):457\u2013462. https:\/\/doi.org\/10.1038\/nbt1081","journal-title":"Nat Biotechnol"},{"issue":"7","key":"41_CR53","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1021\/acs.molpharmaceut.7b00352","volume":"14","author":"MA Obeid","year":"2017","unstructured":"Obeid MA, Elburi A, Young LC, Mullen AB, Tate RJ, Ferro VA (2017) Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells. Mol Pharm 14(7):2450\u20132458","journal-title":"Mol Pharm"},{"issue":"4","key":"41_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.gt.3302868","volume":"14","author":"N Nakai","year":"2007","unstructured":"Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S, Mazda O (2007) Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 14(4):357\u2013365. https:\/\/doi.org\/10.1038\/sj.gt.3302868","journal-title":"Gene Ther"},{"issue":"6","key":"41_CR55","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/s0092-8674(02)00762-6","volume":"109","author":"GG McGill","year":"2002","unstructured":"McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR, Fisher DE (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109(6):707\u2013718. https:\/\/doi.org\/10.1016\/s0092-8674(02)00762-6","journal-title":"Cell"},{"issue":"9","key":"41_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6499","volume":"5","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang Y, Zeng Q, Zeng H, Liu X, Wu P, Xie H, He L, Long Z, Lu X (2019) Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes. Sci Adv 5(9):eaaw6499","journal-title":"Sci Adv"},{"key":"41_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","volume":"57","author":"CF Bennett","year":"2017","unstructured":"Bennett CF, Baker BF, Pham N, Swayze E, Geary RS (2017) Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 57:81\u2013105. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104846","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"41_CR58","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jmb.2004.10.082","volume":"345","author":"M Andronescu","year":"2005","unstructured":"Andronescu M, Zhang ZC, Condon A (2005) Secondary structure prediction of interacting RNA molecules. J Mol Biol 345(5):987\u20131001. https:\/\/doi.org\/10.1016\/j.jmb.2004.10.082","journal-title":"J Mol Biol"},{"key":"41_CR59","volume-title":"Novel anticancer agents","author":"R Zhang","year":"2006","unstructured":"Zhang R, Wang H (2006) Antisense strategies for the development of novel cancer therapeutics. In: Adjei AA, Buolamwini JK (eds) Novel anticancer agents. Elsevier, Amsterdam"},{"issue":"1","key":"41_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","volume":"2","author":"SK Denduluri","year":"2015","unstructured":"Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2(1):13\u201325","journal-title":"Genes Dis"},{"issue":"2","key":"41_CR61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/pharmaceutics10020065","volume":"10","author":"M Karim","year":"2018","unstructured":"Karim M, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH (2018) Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics 10(2):65","journal-title":"Pharmaceutics"},{"issue":"1","key":"41_CR62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1582-4934.2008.00556.x","volume":"13","author":"AM Krichevsky","year":"2009","unstructured":"Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted RNA. J Cell Mol Med 13(1):39\u201353","journal-title":"J Cell Mol Med"},{"issue":"5","key":"41_CR63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/1566524043360410","volume":"4","author":"S Bagheri","year":"2004","unstructured":"Bagheri S, Kashani-Sabet M (2004) Ribozymes in the age of molecular therapeutics. Curr Mol Med 4(5):489\u2013506. https:\/\/doi.org\/10.2174\/1566524043360410","journal-title":"Curr Mol Med"},{"issue":"6","key":"41_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030109","volume":"3","author":"M Wood","year":"2007","unstructured":"Wood M, Yin H, McClorey G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3(6):e109. https:\/\/doi.org\/10.1371\/journal.pgen.0030109","journal-title":"PLoS Genet"},{"issue":"2","key":"41_CR65","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bbrc.2006.08.073","volume":"349","author":"H-S Jung","year":"2006","unstructured":"Jung H-S, Lee S-W (2006) Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing. Biochem Biophys Res Commun 349(2):556\u2013563. https:\/\/doi.org\/10.1016\/j.bbrc.2006.08.073","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"41_CR66","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.gt.3301065","volume":"7","author":"T Suzuki","year":"2000","unstructured":"Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, Holm P, Curiel D, Kashani-Sabet M, Scanlon K (2000) Adenovirus-mediated ribozyme targeting of HER-2\/neu inhibits in vivo growth of breast cancer cells. Gene Ther 7(3):241\u2013248","journal-title":"Gene Ther"},{"issue":"4","key":"41_CR67","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11523-012-0236-7","volume":"7","author":"F Dai","year":"2012","unstructured":"Dai F, Zhang Y, Zhu X, Shan N, Chen Y (2012) Anticancer role of MUC1 aptamer\u2013miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol 7(4):217\u2013225","journal-title":"Target Oncol"},{"issue":"7","key":"41_CR68","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/mt.2016.85","volume":"24","author":"DW Binzel","year":"2016","unstructured":"Binzel DW, Shu Y, Li H, Sun M, Zhang Q, Shu D, Guo B, Guo P (2016) Specific delivery of miRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Mol Ther 24(7):1267\u20131277","journal-title":"Mol Ther"},{"issue":"2","key":"41_CR69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1567201817666200106104332","volume":"17","author":"G Shrivastava","year":"2020","unstructured":"Shrivastava G, Bakshi HA, Aljabali AA, Mishra V, Faruck LH, Charbe NB, Kesharwani P, Chellappan DK, Dua K, Tambuwala MM (2020) Nucleic acid aptamers as potential nucleus targeted drug delivery system. Curr Drug Deliv 17(2):101\u2013111. https:\/\/doi.org\/10.2174\/1567201817666200106104332","journal-title":"Curr Drug Deliv"},{"key":"41_CR70","unstructured":"Bakshi H, Tambuwala MM (2019) Nucleus targeting: overcoming barriers with nucleic acid aptamers. Curr Drug Deliv"},{"issue":"15","key":"41_CR71","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/bloodadvances.2017004705","volume":"1","author":"T Tanno","year":"2017","unstructured":"Tanno T, Zhang P, Lazarski CA, Liu Y, Zheng P (2017) An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth. Blood Adv 1(15):1107\u20131119","journal-title":"Blood Adv"},{"issue":"11","key":"41_CR72","first-page":"1","volume":"2","author":"MM Al Qaraghuli","year":"2017","unstructured":"Al Qaraghuli MM, Alzahrani AR, Niwasabutra K, Obeid MA, Ferro VA (2017) Where traditional drug discovery meets modern technology in the quest for new drugs. Ann Pharmacol Pharm 2(11):1\u20135","journal-title":"Ann Pharmacol Pharm"},{"issue":"6","key":"41_CR73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.addr.2007.04.006","volume":"59","author":"M Sch\u00e4fer-Korting","year":"2007","unstructured":"Sch\u00e4fer-Korting M, Mehnert W, Korting H-C (2007) Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59(6):427\u2013443","journal-title":"Adv Drug Deliv Rev"},{"key":"41_CR74","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","volume":"112","author":"A Garces","year":"2018","unstructured":"Garces A, Amaral MH, Sousa Lobo JM, Silva AC (2018) Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci 112:159\u2013167. https:\/\/doi.org\/10.1016\/j.ejps.2017.11.023","journal-title":"Eur J Pharm Sci"},{"issue":"3 Pt A","key":"41_CR75","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","volume":"85","author":"K Hadinoto","year":"2013","unstructured":"Hadinoto K, Sundaresan A, Cheow WS (2013) Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85(3 Pt A):427\u2013443. https:\/\/doi.org\/10.1016\/j.ejpb.2013.07.002","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"41_CR76","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","volume":"366","author":"J Pardeike","year":"2009","unstructured":"Pardeike J, Hommoss A, Muller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366(1\u20132):170\u2013184. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.10.003","journal-title":"Int J Pharm"},{"issue":"9","key":"41_CR77","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","volume":"56","author":"SA Wissing","year":"2004","unstructured":"Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56(9):1257\u20131272. https:\/\/doi.org\/10.1016\/j.addr.2003.12.002","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"41_CR78","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.addr.2007.05.002","volume":"59","author":"RH M\u00fcller","year":"2007","unstructured":"M\u00fcller RH (2007) Lipid nanoparticles: recent advances. Adv Drug Deliv Rev 59(6):375\u2013376. https:\/\/doi.org\/10.1016\/j.addr.2007.05.002","journal-title":"Adv Drug Deliv Rev"},{"key":"41_CR79","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.msec.2016.05.119","volume":"68","author":"M Geszke-Moritz","year":"2016","unstructured":"Geszke-Moritz M, Moritz M (2016) Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Mater Sci Eng C Mater Biol Appl 68:982\u2013994. https:\/\/doi.org\/10.1016\/j.msec.2016.05.119","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"1","key":"41_CR80","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0939-6411(00)00087-4","volume":"50","author":"RH Muller","year":"2000","unstructured":"Muller RH, Mader K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery \u2013 a review of the state of the art. Eur J Pharm Biopharm 50(1):161\u2013177. https:\/\/doi.org\/10.1016\/s0939-6411(00)00087-4","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"41_CR81","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.msec.2013.01.037","volume":"33","author":"S Kumar","year":"2013","unstructured":"Kumar S, Randhawa JK (2013) High melting lipid based approach for drug delivery: solid lipid nanoparticles. Mater Sci Eng C Mater Biol Appl 33(4):1842\u20131852. https:\/\/doi.org\/10.1016\/j.msec.2013.01.037","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"41_CR82","volume-title":"Integrative nanomedicine for new therapies","author":"M Rezigue","year":"2020","unstructured":"Rezigue M (2020) Lipid and polymeric nanoparticles: drug delivery applications. In: Krishnan A, Chuturgoon A (eds) Integrative nanomedicine for new therapies. Springer, Cham"},{"issue":"19","key":"41_CR83","doi-asserted-by":"publisher","first-page":"195101","DOI":"10.1088\/1361-6528\/ab6d9c","volume":"31","author":"MA Obeid","year":"2020","unstructured":"Obeid MA, Gany SAS, Gray AI, Young L, Igoli JO, Ferro VA (2020) Niosome-encapsulated balanocarpol: compound isolation, characterisation, and cytotoxicity evaluation against human breast and ovarian cancer cell lines. Nanotechnology 31(19):195101","journal-title":"Nanotechnology"},{"issue":"2","key":"41_CR84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/2211738506666180420165547","volume":"6","author":"CK Gamboa","year":"2018","unstructured":"Gamboa CK, Samir R, Wu C, Mu H (2018) Solid lipid particles as drug carriers \u2013 effects of particle preparation methods and lipid excipients on particle characteristics. Pharm Nanotechnol 6(2):124\u2013132. https:\/\/doi.org\/10.2174\/2211738506666180420165547","journal-title":"Pharm Nanotechnol"},{"issue":"4","key":"41_CR85","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1517\/17425247.2012.666967","volume":"9","author":"C Puglia","year":"2012","unstructured":"Puglia C, Bonina F (2012) Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 9(4):429\u2013441. https:\/\/doi.org\/10.1517\/17425247.2012.666967","journal-title":"Expert Opin Drug Deliv"},{"issue":"Suppl 1","key":"41_CR86","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/s0169-409x(02)00118-7","volume":"54","author":"RH Muller","year":"2002","unstructured":"Muller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54(Suppl 1):S131\u2013S155. https:\/\/doi.org\/10.1016\/s0169-409x(02)00118-7","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"41_CR87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","volume":"242","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller RH, Radtke M, Wissing SA (2002) Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242(1):121\u2013128. https:\/\/doi.org\/10.1016\/S0378-5173(02)00180-1","journal-title":"Int J Pharm"},{"issue":"1","key":"41_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/187221013804484827","volume":"7","author":"CL Fang","year":"2013","unstructured":"Fang CL, Al-Suwayeh SA, Fang JY (2013) Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 7(1):41\u201355","journal-title":"Recent Pat Nanotechnol"},{"issue":"11","key":"41_CR89","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4155\/tde-2017-0060","volume":"8","author":"MA Obeid","year":"2017","unstructured":"Obeid MA, Al Qaraghuli MM, Alsaadi M, Alzahrani AR, Niwasabutra K, Ferro VA (2017) Delivering natural products and biotherapeutics to improve drug efficacy. Ther Deliv 8(11):947\u2013956","journal-title":"Ther Deliv"},{"issue":"1","key":"41_CR90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0378-5173(95)04286-5","volume":"129","author":"H Bunjes","year":"1996","unstructured":"Bunjes H, Westesen K, Koch MHJ (1996) Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129(1):159\u2013173. https:\/\/doi.org\/10.1016\/0378-5173(95)04286-5","journal-title":"Int J Pharm"},{"issue":"6","key":"41_CR91","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","volume":"59","author":"AA Date","year":"2007","unstructured":"Date AA, Joshi MD, Patravale VB (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59(6):505\u2013521. https:\/\/doi.org\/10.1016\/j.addr.2007.04.009","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"41_CR92","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ijpharm.2017.06.052","volume":"528","author":"KM El-Say","year":"2017","unstructured":"El-Say KM, El-Sawy HS (2017) Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm 528(1\u20132):675\u2013691. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.06.052","journal-title":"Int J Pharm"},{"key":"41_CR93","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ijpharm.2019.05.042","volume":"565","author":"H Choudhury","year":"2019","unstructured":"Choudhury H, Gorain B, Pandey M, Khurana RK, Kesharwani P (2019) Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm 565:509\u2013522. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.042","journal-title":"Int J Pharm"},{"issue":"7","key":"41_CR94","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.progpolymsci.2011.01.001","volume":"36","author":"JP Rao","year":"2011","unstructured":"Rao JP, Geckeler KE (2011) Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci 36(7):887\u2013913. https:\/\/doi.org\/10.1016\/j.progpolymsci.2011.01.001","journal-title":"Prog Polym Sci"},{"issue":"4","key":"41_CR95","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1872211313666190123153711","volume":"12","author":"N Erdogar","year":"2018","unstructured":"Erdogar N, Akkin S, Bilensoy E (2018) Nanocapsules for drug delivery: an updated review of the last decade. Recent Pat Drug Deliv Formul 12(4):252\u2013266. https:\/\/doi.org\/10.2174\/1872211313666190123153711","journal-title":"Recent Pat Drug Deliv Formul"},{"issue":"3","key":"41_CR96","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/wnan.1211","volume":"5","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Tsai PC, Ramezanli T, Michniak-Kohn BB (2013) Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5(3):205\u2013218. https:\/\/doi.org\/10.1002\/wnan.1211","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"41_CR97","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijpharm.2019.03.011","volume":"561","author":"A George","year":"2019","unstructured":"George A, Shah PA, Shrivastav PS (2019) Natural biodegradable polymers based nano-formulations for drug delivery: a review. Int J Pharm 561:244\u2013264. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.03.011","journal-title":"Int J Pharm"},{"key":"41_CR98","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jconrel.2015.10.049","volume":"240","author":"R Goyal","year":"2016","unstructured":"Goyal R, Macri LK, Kaplan HM, Kohn J (2016) Nanoparticles and nanofibers for topical drug delivery. J Control Release 240:77\u201392. https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.049","journal-title":"J Control Release"},{"issue":"1","key":"41_CR99","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijpharm.2017.09.005","volume":"532","author":"AS Deshmukh","year":"2017","unstructured":"Deshmukh AS, Chauhan PN, Noolvi MN, Chaturvedi K, Ganguly K, Shukla SS, Nadagouda MN, Aminabhavi TM (2017) Polymeric micelles: basic research to clinical practice. Int J Pharm 532(1):249\u2013268. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.09.005","journal-title":"Int J Pharm"},{"issue":"5","key":"41_CR100","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1389200218666170222145240","volume":"18","author":"S Gungor","year":"2017","unstructured":"Gungor S, Rezigue M (2017) Nanocarriers mediated topical drug delivery for psoriasis treatment. Curr Drug Metab 18(5):454\u2013468. https:\/\/doi.org\/10.2174\/1389200218666170222145240","journal-title":"Curr Drug Metab"},{"issue":"1","key":"41_CR101","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1208\/s12249-014-0251-3","volume":"16","author":"H Cho","year":"2015","unstructured":"Cho H, Lai TC, Tomoda K, Kwon GS (2015) Polymeric micelles for multi-drug delivery in cancer. AAPS PharmSciTech 16(1):10\u201320. https:\/\/doi.org\/10.1208\/s12249-014-0251-3","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"41_CR102","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00280-017-3273-1","volume":"79","author":"M Yousefpour Marzbali","year":"2017","unstructured":"Yousefpour Marzbali M, Yari Khosroushahi A (2017) Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review. Cancer Chemother Pharmacol 79(4):637\u2013649. https:\/\/doi.org\/10.1007\/s00280-017-3273-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"41_CR103","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1166\/jnn.2015.9713","volume":"15","author":"BP Reddy","year":"2015","unstructured":"Reddy BP, Yadav HK, Nagesha DK, Raizaday A, Karim A (2015) Polymeric micelles as novel carriers for poorly soluble drugs\u2014a review. J Nanosci Nanotechnol 15(6):4009\u20134018. https:\/\/doi.org\/10.1166\/jnn.2015.9713","journal-title":"J Nanosci Nanotechnol"},{"key":"41_CR104","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejpb.2016.12.019","volume":"113","author":"M Cagel","year":"2017","unstructured":"Cagel M, Tesan FC, Bernabeu E, Salgueiro MJ, Zubillaga MB, Moretton MA, Chiappetta DA (2017) Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur J Pharm Biopharm 113:211\u2013228. https:\/\/doi.org\/10.1016\/j.ejpb.2016.12.019","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"41_CR105","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0885328216685755","volume":"31","author":"G Liu","year":"2017","unstructured":"Liu G, Li K, Wang H (2017) Polymeric micelles based on PEGylated chitosan-g-lipoic acid as carrier for efficient intracellular drug delivery. J Biomater Appl 31(7):1039\u20131048. https:\/\/doi.org\/10.1177\/0885328216685755","journal-title":"J Biomater Appl"},{"issue":"1","key":"41_CR106","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11095-015-1784-1","volume":"33","author":"A Gothwal","year":"2016","unstructured":"Gothwal A, Khan I, Gupta U (2016) Polymeric micelles: recent advancements in the delivery of anticancer drugs. Pharm Res 33(1):18\u201339. https:\/\/doi.org\/10.1007\/s11095-015-1784-1","journal-title":"Pharm Res"},{"issue":"1","key":"41_CR107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/cr068212n","volume":"109","author":"RK Tekade","year":"2009","unstructured":"Tekade RK, Kumar PV, Jain NK (2009) Dendrimers in oncology: an expanding horizon. Chem Rev 109(1):49\u201387. https:\/\/doi.org\/10.1021\/cr068212n","journal-title":"Chem Rev"},{"issue":"8","key":"41_CR108","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1211\/jpp\/61.08.0002","volume":"61","author":"V Gajbhiye","year":"2009","unstructured":"Gajbhiye V, Palanirajan VK, Tekade RK, Jain NK (2009) Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 61(8):989\u20131003. https:\/\/doi.org\/10.1211\/jpp\/61.08.0002","journal-title":"J Pharm Pharmacol"},{"key":"41_CR109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4172\/2161-0703.1000260","volume":"6","author":"MM Al Qaraghuli","year":"2017","unstructured":"Al Qaraghuli MM, Obeid MA, Aldulaimi O, Ferro VA (2017) Control of malaria by bio-therapeutics and drug delivery systems. J Med Microb Diagn 6:3. https:\/\/doi.org\/10.4172\/2161-0703.1000260","journal-title":"J Med Microb Diagn"},{"issue":"5","key":"41_CR110","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/1061186x.2013.771778","volume":"21","author":"U Agrawal","year":"2013","unstructured":"Agrawal U, Mehra NK, Gupta U, Jain NK (2013) Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target 21(5):497\u2013506. https:\/\/doi.org\/10.3109\/1061186x.2013.771778","journal-title":"J Drug Target"},{"key":"41_CR111","doi-asserted-by":"publisher","first-page":"630654","DOI":"10.1155\/2013\/630654","volume":"2013","author":"J Wu","year":"2013","unstructured":"Wu J, Huang W, He Z (2013) Dendrimers as carriers for siRNA delivery and gene silencing: a review. Sci World J 2013:630654. https:\/\/doi.org\/10.1155\/2013\/630654","journal-title":"Sci World J"},{"issue":"3","key":"41_CR112","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jconrel.2013.05.020","volume":"170","author":"M Pradhan","year":"2013","unstructured":"Pradhan M, Singh D, Singh MR (2013) Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Control Release 170(3):380\u2013395. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.020","journal-title":"J Control Release"},{"issue":"1\u20132","key":"41_CR113","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijpharm.2016.11.015","volume":"516","author":"MA Obeid","year":"2017","unstructured":"Obeid MA, Khadra I, Mullen AB, Tate RJ, Ferro VA (2017) The effects of hydration media on the characteristics of non-ionic surfactant vesicles (NISV) prepared by microfluidics. Int J Pharm 516(1\u20132):52\u201360","journal-title":"Int J Pharm"},{"issue":"4\u20135","key":"41_CR114","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejps.2008.05.002","volume":"34","author":"GM El Maghraby","year":"2008","unstructured":"El Maghraby GM, Barry BW, Williams AC (2008) Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 34(4\u20135):203\u2013222. https:\/\/doi.org\/10.1016\/j.ejps.2008.05.002","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"41_CR115","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1211\/jpp.58.4.0001","volume":"58","author":"GM El Maghraby","year":"2006","unstructured":"El Maghraby GM, Williams AC, Barry BW (2006) Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol 58(4):415\u2013429. https:\/\/doi.org\/10.1211\/jpp.58.4.0001","journal-title":"J Pharm Pharmacol"},{"issue":"1-2","key":"41_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.12.005","volume":"332","author":"MM Elsayed","year":"2007","unstructured":"Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM (2007) Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 332(1-2):1\u201316. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.12.005","journal-title":"Int J Pharm"},{"key":"41_CR117","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.015","volume":"185","author":"S Moghassemi","year":"2014","unstructured":"Moghassemi S, Hadjizadeh A (2014) Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release 185:22\u201336. https:\/\/doi.org\/10.1016\/j.jconrel.2014.04.015","journal-title":"J Control Release"},{"key":"41_CR118","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/ijn.S105016","volume":"11","author":"IM Abdulbaqi","year":"2016","unstructured":"Abdulbaqi IM, Darwis Y, Khan NA, Assi RA, Khan AA (2016) Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine 11:2279\u20132304. https:\/\/doi.org\/10.2147\/ijn.S105016","journal-title":"Int J Nanomedicine"},{"issue":"1\u20132","key":"41_CR119","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijpharm.2017.02.007","volume":"521","author":"MA Obeid","year":"2017","unstructured":"Obeid MA, Gebril AM, Tate RJ, Mullen AB, Ferro VA (2017) Comparison of the physical characteristics of monodisperse non-ionic surfactant vesicles (NISV) prepared using different manufacturing methods. Int J Pharm 521(1\u20132):54\u201360","journal-title":"Int J Pharm"},{"key":"41_CR120","volume-title":"Drugs and the pharmaceutical sciences","author":"Y Pathak","year":"2009","unstructured":"Pathak Y, Thassu D (2009) Drug delivery nanoparticles formulation and characterization. In: Pathak Y, Thassu D (eds) Drugs and the pharmaceutical sciences. CRC Press, FL"},{"issue":"9","key":"41_CR121","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/17425247.2018.1517747","volume":"15","author":"D Wang","year":"2018","unstructured":"Wang D, Sun Y, Liu Y, Meng F, Lee RJ (2018) Clinical translation of immunoliposomes for cancer therapy: recent perspectives. Expert Opin Drug Deliv 15(9):893\u2013903. https:\/\/doi.org\/10.1080\/17425247.2018.1517747","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"41_CR122","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3109\/10717544.2015.1027015","volume":"23","author":"X Wang","year":"2016","unstructured":"Wang X, Song Y, Su Y, Tian Q, Li B, Quan J, Deng Y (2016) Are PEGylated liposomes better than conventional liposomes? A special case for vincristine. Drug Deliv 23(4):1092\u20131100. https:\/\/doi.org\/10.3109\/10717544.2015.1027015","journal-title":"Drug Deliv"},{"key":"41_CR123","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/ijn.S86186","volume":"10","author":"A Ascenso","year":"2015","unstructured":"Ascenso A, Raposo S, Batista C, Cardoso P, Mendes T, Praca FG, Bentley MV, Simoes S (2015) Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes. Int J Nanomedicine 10:5837\u20135851. https:\/\/doi.org\/10.2147\/ijn.S86186","journal-title":"Int J Nanomedicine"},{"key":"41_CR124","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.colsurfb.2011.12.004","volume":"92","author":"CK Song","year":"2012","unstructured":"Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD (2012) A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro\/in vivo evaluation. Colloids Surf B Biointerfaces 92:299\u2013304. https:\/\/doi.org\/10.1016\/j.colsurfb.2011.12.004","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"2 Pt 1","key":"41_CR125","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/s0006-3495(03)74917-0","volume":"84","author":"G Cevc","year":"2003","unstructured":"Cevc G, Gebauer D (2003) Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. Biophys J 84(2 Pt 1):1010\u20131024. https:\/\/doi.org\/10.1016\/s0006-3495(03)74917-0","journal-title":"Biophys J"},{"key":"41_CR126","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2147\/ijn.S33048","volume":"8","author":"EL Romero","year":"2013","unstructured":"Romero EL, Morilla MJ (2013) Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. Int J Nanomedicine 8:3171\u20133186. https:\/\/doi.org\/10.2147\/ijn.S33048","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"41_CR127","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.addr.2003.10.028","volume":"56","author":"G Cevc","year":"2004","unstructured":"Cevc G (2004) Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 56(5):675\u2013711. https:\/\/doi.org\/10.1016\/j.addr.2003.10.028","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"41_CR128","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1081\/ddc-120025458","volume":"29","author":"S Jain","year":"2003","unstructured":"Jain S, Jain P, Umamaheshwari RB, Jain NK (2003) Transfersomes\u2014a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm 29(9):1013\u20131026. https:\/\/doi.org\/10.1081\/ddc-120025458","journal-title":"Drug Dev Ind Pharm"},{"issue":"3\u20134","key":"41_CR129","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<406::Aid-ddr23>3.0.Co;2-m","volume":"50","author":"E Touitou","year":"2000","unstructured":"Touitou E, Godin B, Weiss C (2000) Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev Res 50(3\u20134):406\u2013415. https:\/\/doi.org\/10.1002\/1098-2299(200007\/08)50:3\/4<406::Aid-ddr23>3.0.Co;2-m","journal-title":"Drug Dev Res"},{"issue":"3","key":"41_CR130","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0168-3659(99)00222-9","volume":"65","author":"E Touitou","year":"2000","unstructured":"Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M (2000) Ethosomes \u2013 novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 65(3):403\u2013418. https:\/\/doi.org\/10.1016\/s0168-3659(99)00222-9","journal-title":"J Control Release"},{"issue":"3","key":"41_CR131","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/nano8030174","volume":"8","author":"AAA Aljabali","year":"2018","unstructured":"Aljabali AAA, Akkam Y, Al Zoubi MS, Al-Batayneh KM, Al-Trad B, Abo Alrob O, Alkilany AM, Benamara M, Evans DJ (2018) Synthesis of gold nanoparticles using leaf extract of ziziphus zizyphus and their antimicrobial activity. Nanomaterials (Basel) 8(3):174. https:\/\/doi.org\/10.3390\/nano8030174","journal-title":"Nanomaterials (Basel)"},{"key":"41_CR132","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3762\/bjnano.10.195","volume":"10","author":"A Aljabali","year":"2019","unstructured":"Aljabali A, AL Zoubi M, Al-Batanyeh K, Al-Radaideh A, Obeid M, Al Sharabi A, Alshaer W, Abufares B, Al-Zanati T, Tambuwala M, Akbar N, Evans D (2019) Gold-coated plant virus as computed tomography imaging contrast agent. Beilstein J Nanotechnol 10:1983\u20131993","journal-title":"Beilstein J Nanotechnol"},{"key":"41_CR133","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cis.2017.01.007","volume":"249","author":"I Capek","year":"2017","unstructured":"Capek I (2017) Polymer decorated gold nanoparticles in nanomedicine conjugates. Adv Colloid Interface 249:386\u2013399. https:\/\/doi.org\/10.1016\/j.cis.2017.01.007","journal-title":"Adv Colloid Interface"},{"issue":"7","key":"41_CR134","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00775-019-01694-x","volume":"24","author":"JG Nirmala","year":"2019","unstructured":"Nirmala JG, Beck A, Mehta S, Lopus M (2019) Perturbation of tubulin structure by stellate gold nanoparticles retards MDA-MB-231 breast cancer cell viability. J Biol Inorg Chem 24(7):999\u20131007. https:\/\/doi.org\/10.1007\/s00775-019-01694-x","journal-title":"J Biol Inorg Chem"},{"key":"41_CR135","doi-asserted-by":"publisher","unstructured":"Singh P, Pandit S, Mokkapati V, Garg A, Ravikumar V, Mijakovic I (2018) Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci 19(7). https:\/\/doi.org\/10.3390\/ijms19071979","DOI":"10.3390\/ijms19071979"},{"key":"41_CR136","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijpharm.2019.01.064","volume":"561","author":"I Khadra","year":"2019","unstructured":"Khadra I, Obeid MA, Dunn C, Watts S, Halbert G, Ford S, Mullen A (2019) Characterisation and optimisation of diclofenac sodium orodispersible thin film formulation. Int J Pharm 561:43\u201346","journal-title":"Int J Pharm"},{"issue":"5473","key":"41_CR137","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"P-A Oldenborg","year":"2000","unstructured":"Oldenborg P-A, Zheleznyak A, Fang Y-F, Lagenaur CF, Gresham HD, Lindberg FP (2000) Role of CD47 as a marker of self on red blood cells. Science 288(5473):2051\u20132054","journal-title":"Science"},{"issue":"2","key":"41_CR138","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271\u2013285","journal-title":"Cell"},{"issue":"10","key":"41_CR139","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/mt.2013.135","volume":"21","author":"Y Wang","year":"2013","unstructured":"Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, Huang L (2013) Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther 21(10):1919\u20131929","journal-title":"Mol Ther"},{"issue":"4","key":"41_CR140","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1021\/nn500216y","volume":"8","author":"Z Xu","year":"2014","unstructured":"Xu Z, Wang Y, Zhang L, Huang L (2014) Nanoparticle-delivered transforming growth factor-\u03b2 siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 8(4):3636\u20133645","journal-title":"ACS Nano"},{"issue":"1","key":"41_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1572-1000(05)00030-X","volume":"2","author":"AP Castano","year":"2005","unstructured":"Castano AP, Demidova TN, Hamblin MR (2005) Mechanisms in photodynamic therapy: part two\u2014cellular signaling, cell metabolism and modes of cell death. Photodiagn Photodyn 2(1):1\u201323","journal-title":"Photodiagn Photodyn"},{"issue":"2","key":"41_CR142","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1572-1000(05)00060-8","volume":"2","author":"AP Castano","year":"2005","unstructured":"Castano AP, Demidova TN, Hamblin MR (2005) Mechanisms in photodynamic therapy: part three\u2014photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagn Photodyn 2(2):91\u2013106","journal-title":"Photodiagn Photodyn"},{"issue":"4","key":"41_CR143","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1572-1000(05)00007-4","volume":"1","author":"AP Castano","year":"2004","unstructured":"Castano AP, Demidova TN, Hamblin MR (2004) Mechanisms in photodynamic therapy: part one\u2014photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn 1(4):279\u2013293","journal-title":"Photodiagn Photodyn"},{"issue":"14","key":"41_CR144","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1073\/pnas.0709256105","volume":"105","author":"AP Castano","year":"2008","unstructured":"Castano AP, Mroz P, Wu MX, Hamblin MR (2008) Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A 105(14):5495\u20135500","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"41_CR145","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1021\/acs.nanolett.6b01994","volume":"16","author":"D Wang","year":"2016","unstructured":"Wang D, Wang T, Liu J, Yu H, Jiao S, Feng B, Zhou F, Fu Y, Yin Q, Zhang P (2016) Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced cancer photodynamic immunotherapy. Nano Lett 16(9):5503\u20135513","journal-title":"Nano Lett"},{"issue":"4","key":"41_CR146","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1172\/JCI200422206","volume":"114","author":"JD Wu","year":"2004","unstructured":"Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114(4):560\u2013568","journal-title":"J Clin Invest"},{"issue":"3","key":"41_CR147","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1073\/pnas.92.3.811","volume":"92","author":"JG Gribben","year":"1995","unstructured":"Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Ke X, Gray GS (1995) CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 92(3):811\u2013815","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"41_CR148","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99(19):12293\u201312297","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"41_CR149","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203(4):883\u2013895","journal-title":"J Exp Med"},{"issue":"2","key":"41_CR150","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.semcancer.2005.11.006","volume":"16","author":"K Khazaie","year":"2006","unstructured":"Khazaie K, Von Boehmer H (2006) The impact of CD4+ CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16(2):124\u2013136. https:\/\/doi.org\/10.1016\/j.semcancer.2005.11.006","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"41_CR151","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298\u2013306","journal-title":"Nat Rev Cancer"},{"key":"41_CR152","doi-asserted-by":"publisher","unstructured":"Obeid MA, Teeravatcharoenchai T, Connell D, Niwasabutra K, Hussain M, Carter K, Ferro VA (2020) Examination of the effect of niosome preparation methods in encapsulating model antigens on the vesicle characteristics and their ability to induce immune responses. J Liposome Res. https:\/\/doi.org\/10.1080\/08982104.2020.1768110","DOI":"10.1080\/08982104.2020.1768110"},{"key":"41_CR153","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2016.01.044","volume":"231","author":"S-Y Li","year":"2016","unstructured":"Li S-Y, Liu Y, Xu C-F, Shen S, Sun R, Du X-J, Xia J-X, Zhu Y-H, Wang J (2016) Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J Control Release 231:17\u201328","journal-title":"J Control Release"},{"issue":"1","key":"41_CR154","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3762\/bjnano.10.177","volume":"10","author":"MA Obeid","year":"2019","unstructured":"Obeid MA, Khadra I, Albaloushi A, Mullin M, Alyamani H, Ferro VA (2019) Microfluidic manufacturing of different niosomes nanoparticles for curcumin encapsulation: physical characteristics, encapsulation efficacy, and drug release. Beilstein J Nanotechnol 10(1):1826\u20131832","journal-title":"Beilstein J Nanotechnol"},{"issue":"1","key":"41_CR155","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49\u201361","journal-title":"Immunity"},{"issue":"6","key":"41_CR156","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1615\/critrevimmunol.v32.i6.10","volume":"32","author":"C Mills","year":"2012","unstructured":"Mills C (2012) M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol 32(6):463\u2013488. https:\/\/doi.org\/10.1615\/critrevimmunol.v32.i6.10","journal-title":"Crit Rev Immunol"},{"issue":"5","key":"41_CR157","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"A Sica","year":"2008","unstructured":"Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18(5):349\u2013355. https:\/\/doi.org\/10.1016\/j.semcancer.2008.03.004","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"41_CR158","doi-asserted-by":"publisher","first-page":"9536","DOI":"10.1021\/acsnano.7b05465","volume":"11","author":"Y Qian","year":"2017","unstructured":"Qian Y, Qiao S, Dai Y, Xu G, Dai B, Lu L, Yu X, Luo Q, Zhang Z (2017) Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages. ACS Nano 11(9):9536\u20139549","journal-title":"ACS Nano"},{"issue":"20","key":"41_CR159","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/sj.onc.1206453","volume":"22","author":"C Tellez","year":"2003","unstructured":"Tellez C, Bar-Eli M (2003) Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22(20):3130\u20133137","journal-title":"Oncogene"},{"issue":"47","key":"41_CR160","doi-asserted-by":"publisher","first-page":"46632","DOI":"10.1074\/jbc.M309159200","volume":"278","author":"C Tellez","year":"2003","unstructured":"Tellez C, McCarty M, Ruiz M, Bar-Eli M (2003) Loss of activator protein-2\u03b1 results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 278(47):46632\u201346642","journal-title":"J Biol Chem"},{"issue":"6","key":"41_CR161","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.humpath.2005.04.008","volume":"36","author":"D Massi","year":"2005","unstructured":"Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M, Tarantini F, Ketabchi S, Cirino G, Hollenberg MD (2005) Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 36(6):676\u2013685","journal-title":"Hum Pathol"},{"issue":"2","key":"41_CR162","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.jid.5700539","volume":"127","author":"CS Tellez","year":"2007","unstructured":"Tellez CS, Davis DW, Prieto VG, Gershenwald JE, Johnson MM, McCarty MF, Bar-Eli M (2007) Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2\u03b1 and protease-activated receptor-1 expression during melanoma progression. J Investig Dermatol 127(2):387\u2013393","journal-title":"J Investig Dermatol"},{"issue":"1\u20132","key":"41_CR163","doi-asserted-by":"publisher","first-page":"8","DOI":"10.18632\/oncotarget.211","volume":"2","author":"GJ Villares","year":"2011","unstructured":"Villares GJ, Zigler M, Bar-Eli M (2011) The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis-a possible therapeutic target. Oncotarget 2(1\u20132):8","journal-title":"Oncotarget"},{"issue":"21","key":"41_CR164","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1158\/0008-5472.CAN-08-2397","volume":"68","author":"GJ Villares","year":"2008","unstructured":"Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK (2008) Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68(21):9078\u20139086","journal-title":"Cancer Res"},{"issue":"6","key":"41_CR165","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/00001813-200507000-00002","volume":"16","author":"N Jing","year":"2005","unstructured":"Jing N, Tweardy DJ (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16(6):601\u2013607","journal-title":"Anticancer Drugs"},{"issue":"6","key":"41_CR166","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.biomaterials.2009.11.003","volume":"31","author":"A Alshamsan","year":"2010","unstructured":"Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uluda\u011f H (2010) The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31(6):1420\u20131428","journal-title":"Biomaterials"},{"key":"41_CR167","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.colsurfb.2016.05.076","volume":"146","author":"S Labala","year":"2016","unstructured":"Labala S, Jose A, Venuganti VVK (2016) Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma. Colloids Surf B Biointerfaces 146:188\u2013197","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"2","key":"41_CR168","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ijpharm.2017.03.087","volume":"525","author":"S Labala","year":"2017","unstructured":"Labala S, Jose A, Chawla SR, Khan MS, Bhatnagar S, Kulkarni OP, Venuganti VVK (2017) Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles. Int J Pharm 525(2):407\u2013417","journal-title":"Int J Pharm"},{"issue":"3","key":"41_CR169","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/mt.2011.270","volume":"20","author":"Y Yang","year":"2012","unstructured":"Yang Y, Li J, Liu F, Huang L (2012) Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther 20(3):609\u2013615","journal-title":"Mol Ther"},{"issue":"2","key":"41_CR170","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello JE, Jovin IS, Huang Y (2007) Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. YJBM 80(2):51","journal-title":"YJBM"},{"key":"41_CR171","first-page":"991","volume":"11","author":"Z Chen","year":"2016","unstructured":"Chen Z, Zhang T, Wu B, Zhang X (2016) Insights into the therapeutic potential of hypoxia-inducible factor-1\u03b1 small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes. Int J Nanomedicine 11:991","journal-title":"Int J Nanomedicine"},{"issue":"8","key":"41_CR172","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A (2007) Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8):1263\u20131284","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"41_CR173","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/clpt.2013.197","volume":"95","author":"S Jang","year":"2014","unstructured":"Jang S, Atkins M (2014) Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 95(1):24\u201331","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"41_CR174","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2050-7771-1-3","volume":"1","author":"T Huang","year":"2013","unstructured":"Huang T, Zhuge J, Zhang WW (2013) Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR. Biomark Res 1(1):3","journal-title":"Biomark Res"},{"key":"41_CR175","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jconrel.2016.03.010","volume":"228","author":"M Dorrani","year":"2016","unstructured":"Dorrani M, Garbuzenko OB, Minko T, Michniak-Kohn B (2016) Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy. J Control Release 228:150\u2013158","journal-title":"J Control Release"}],"container-title":["Methods in Molecular Biology","Melanoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1205-7_41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T07:09:30Z","timestamp":1615446570000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-1205-7_41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9781071612040","9781071612057"],"references-count":175,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1205-7_41","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"12 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}